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Monascus purpureus is a fungus that had been cultured on the rice in 
eastern Asian countries since thousands years ago and used as a food 
for long years. The fungus produces very valuable metabolites with 
polyketide structure. The most important metabolite is Monacolin K, 
lovastatin or competitive inhibitor of 3-Hydroxy-3-Methylglutaryl- 
Coenzyme A reductase (an affective enzyme in cholesterol synthesis). 
This metabolite has various properties including reducing blood 
cholesterol, preventing infection, and treatment of progressive renal 
disease, a variety of tumors, vascular diseases and bone fractures. In 
this study, Monascus purpureus PTCC5303 has been used for 
lovastatin production in liquid fermentation. The nutritional 
concentrations that were significant in biomass and lovastatin 
production including maltose and MgSO4 were optimized by Response 
Surface Methodology in a mili-bioreactor. The optimum concentration 





respectively. According to our results, maximum lovastatin production 
under optimum conditions including maltose 10 gl
-1





, MnSO4.H2O 0.5 gl
-1





, and pH=7 at 30°C, 130 rpm and flow rate 1.8 l min
-1 
was 
obtained to be 309 µg l
-1 
after 10 days of fermentation period. 
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Cardiovascular diseases (CVDs), particularly 
coronary heart disease (CHD), are among the major 
causes of mortality in the developed countries [1, 2]. 
Atherosclerosis is the underlying disorder in the 
majority of patients presenting CVDs. It is displayed 
when fat, cellular waste products, calcium, and other 
substances, particularly cholesterol, are deposited inside 
the artery, gradually reducing the inside diameter of the 
artery. This may cause blockage of large and medium 
sized arteries [1,3]. Numerous clinical and epidemiolo- 
 
 
gical trials have shown the efficacy of lowering 
cholesterol for reducing CHD risk. Therefore, for 
prevention of atherosclerosis blood cholesterol level 
should be controlled [4]. Endo [5] extracted monacolin 
K (also known as Mevinolin, lovastatin or Mevacor) 
from Monascus sp. in 1980. The metabolite is a 
powerful drug for reducing blood cholesterol level, and 
acts as a competitive inhibitor of 3-Hydroxy-3- 
Methylglutaryl-Coenzyme A (HMG-CoA) reductase. 





cholesterol biosynthesis in human liver [5-9]. 
Moreover, it has been proven that monacolin K is 
therapeutically and preventatively effective in the 
treatment of major kind of diseases like atherosclerosis, 
sepsis, peripheral arterial disease, peripheral vascular 
disease, cerebrovascular disease, ischemic disease, 
and bone fracture [9-13]. One of the industrially 
important microbial sources for lovastatin production 
is Monascus sp. Aspergillus sp., especially Monascus 
purpureus was found to be the most significant 
producers of lovastatin [14]. In many studies, A. 
terreus was used for lovastatin production. Monascus 
species are nonpathogenic, and are frequently used in 
food processing whereas Aspergillus species are 
pathogenic, and not safe to consume [11, 15]. 
Monacolin K (C24H36O5) was the first statin drug, which 
was approved by the United States Food and Drug 
Administration in August 1987 [11, 16, 17]. 
Lovastatin should be produced under the 
controlled conditions because fermentation parameters 
are effective in production of Monascus-products. 
Carbon and nitrogen sources regulate the growth and 
production of secondary metabolites in fermentation 
process, whereas these factors’ cost plays a major role 
in selection [18]. Hence, before isolation/extraction of 
lovastatin, optimization of different physical and 
nutritional factors to achieve maximum growth of the 
fungus and optimum lovastatin production is very 
important. 
To decrease the time needed for optimization, the 
use   of   miniature   bioreactors.   Therefore,   rapidly 
metabolizing,  cell  density  in  microbial  cultivations 
using MBRs can be supported, and the amount of the 
products  in  oxygen-dependent  bioprocesses  can  be 
increased. Also growth kinetics and product formation 
at miniature-scale can be scaled up quantitatively [19]. 
There are several techniques for optimization. 
Statistical method has more advantages than 
conventional method that includes less experiment 
numbers, is rapid and reliable, helps understanding 
the interactions between different concentrations of 
nutrients, finds the most suitable condition, and 
forecasts response [16-22]. 
In this study, significant factors effective on 
biomass and lovastatin production by M. purpureus 
were optimized. Response Surface Methodology 
(RSM) for lovastatin production was applied. A 
controlled mili-bioreactor was used for the first time. 
 
2. Materials and Methods 
2.1. Materials and Microorganism 
All materials and culture media for cultivation such 
as potato dextrose agar were obtained from the Merck 
Company. Lovastatin standard was donated by 
PourSina Pharmaceutical Company. Culture of M. 
purpureus PTCC 5303 was purchased from Iranian 
Research Organization for Science and Technology, 
Iran, maintained on slants of potato dextrose agar at 4°C 
, and sub-cultured every 30 days. 
2.2. Fermentation 
All experiments were carried out in 100-ml mili- 
bioreactor containing 30 ml medium as per 
experimental design. A punched mycelium (r= 4.5 
mm) of M. purpureus PTCC 5305 was transferred into 
each cell, and then incubated at 30°C on a rotary shaker 
at 130 rpm with air flow rate of 1.8 Lmin
-1 
for 10 days. 
At the end of the fermentation period, lovastatin and 
biomass production was measured. To measure the dry 
cell weight, the entire volume of the fermented broth 
was filtered through a filter membrane (Whatman No. 
41). The remaining biomass was freeze dried. Biomass 
was measured till the weight was constant. 
 
2.3. Central Composite Design (CCD) 
The variables concentrations, which were jointly 
significant and effective on the biomass and lovastatin 
production, were optimized according to the CCD using 
DESIGN EXPERT software 6.0.10 trial version (Stat- 
Ease, Minneapolis, USA) (Table 1). The relative effects 
of two variables on response were identified from 
dimensional plots. An optimum value of the variables 
for maximum production of lovastatin was determined 
by point prediction tool of the software. Dry cell weight 
of biomass (R1) and lovastatin production (R2) was 
measured as a response in each trial, and the obtained 
data were analyzed. 
 
2.4. Mili-bioreactor 
Designed tests were carried out in a mili-bioreactor 
in the Research Center for New Technologies in Life 
Science Engineering, University of Tehran, Iran. It 
consists of two parts: the shaker-incubator part with the 
main function of mixing and controlling the 
temperature. The mixing rate could be adjusted from 
100 to 500 rpm, and temperature is controlled with 
PT100 sensor around the ambient temperature to 40°C 
with an accuracy of 0.1 centigrade. For lower temper- 
atures, the apparatus was equipped with chiller model 
IKA KV 600; thus, temperatures lower than the ambient 
temperature (down to -20°C) can be achieved. Time can 
be controlled with the same sensors, which were used in 
the first section. 
The second part consists of glass parts, cells, cables 
and connectors. Four tests could be done simultaneously 
by the four independent cells. Each cell has four 
entrance parts: Part one (sampling section), which was 
used for inoculating and adding materials to sterilized 
medium. Part two, which is connected to aeration tube 
and has gas filter. Part three also has gas filter, and is 
connected to sucking gas tube. Part four contains 
Oxygen Transfer Rate sensor. 
 
2.5. Measurement of Lovastatin 
Procedure given by Su et al. [22] for extraction of 
lovastatin was slightly modified. After pre-separating 
the biomass from the culture using a filter paper, a 
certain amount of supernatant was harvested, adjusted 
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to pH 3.0 using 2N H3PO4, and extracted with an equal 
volume of ethyl acetate on a rotary shaker 180 rpm at 
60°C for 2h. The mixture was centrifuged at 3000 ×g 
for 10 min. The organic phase was collected, 
lactonized with 1% trifluoroacetic acid and concen- 
trated. Finally, 95% methanol was added for HPLC 
analysis using spectrophotometric method. All 
samples were filtered through 0.22 μm millexLH 
(Millipore corp., Bedford, MA 01730) before 
injection [22]. 
 
Table 1. Full factorial central composite design matrix of two variables with the observed responses in a mili-bioreactor 
(SD: ±5%) 















2 +1 -1 5.20 5.24 0.190 0.186 
3 -1 +1 5.86 4.92 0.221 0.210 
4 +1 +1 7.36 7.4 0.193 0.172 
5 -1 0 4.66 3.82 0.164 0.101 
6 +1 0 6.40 6.30 0.155 0.179 
7 0 -1 3.66 2.26 0.140 0.127 
8 0 +1 3.10 3.34 0.133 0.152 
9 0 0 3.33 3.34 0.139 0.140 
10 0 0 3.33 3.34 0.139 0.140 
11 0 0 3.33 3.34 0.139 0.140 
12 0 0 3.33 3.34 0.139 0.140 
13 0 0 3.33 3.34 0.139 0.140 
 
For analysis of lovastatin concentration, we used 
HPLC (KNAUER) equipped with a C18 column of 
particle size 5 μm and 250 mm×4.6 mm I.D. and UV 
detector. The chromatogram was monitored at 238 
nm. The mobile phase used acetonitrile and 0.1% 
wv
-1 
trifluoroacetic acid in the ratio of 70:30, 
respectively. The eluent was pumped at a flow rate of 
1mL min
−1
. The injection volume was 20 μL. The 
lovastatin peak was so well separated from the other 
peaks, making reading the quantity of lovastatin very 
easy. 
 
3. Results and Discussion 
3.1. Optimization of lovastatin production in a 
mili-bioreactor 
According to the previous results, Mansoori et 
al. determined maltose and magnesium sulfate as 
significant factors on biomass and lovastatin 
production by Monascus [23]. Therefore, in order to 
optimize the concentration of these variables in the 
mili-bioreactor, 13 experiments were designed. The 
effect of two factors, i.e. maltose and MgSO4.7H2O 
concentrations, their interaction, and the importance 
of each of the mentioned factors were evaluated 
using Minitab software for lovastatin production in a 
mili-bioreactor. According to the CCD, 13 tests with 
five central points were designed. The results of 
these experiments are presented in Table 1. 
 
3.2. Analysis of the data obtained from optimizing 
the biomass production 
Among the test variables used in the study, 
according to p-values, A (maltose), B (MgSO4.7H2O) 
and  A
2    
were  significant  model  terms,  and  are 
presented in a quadratic equation. As a result, 
optimum biomass production is a function of 
mentioned terms. AB and B
2 
terms with P-values 
more than 0.05 were deleted by the software. Also, in 
order to better analysis of the proposed model, R- 
squared is presented. Normally, R
2 
over 0.7 indicate a 
relatively good correlation coefficient; the closer the 
R
2 
value is to 1, the fitter is the model to the 
experimental data. R
2 
value of 0.81 showed 
appropriate overlap of experimental data, and 
predicted the values by the model proposed for 
biomass production. In this case, the value of the 
determination coefficient (R
2
= 0.81), as shown in 
Figure 1, indicates that the sample variation of 81% 
for cell mass production is attributed to the 
independent variables, and only 19% of the total 
variations are not explained by the model. 
The final proposed model for optimum biomass 
production is as Eq.1: 
R1= 3.34 + 1.24 A + 1.08 B + 1.74 A
2                       
Eq. 1 
Where, A and B are the values of the test 
variables, maltose and MgSO4.7H2O, respectively. 
The effectiveness of maltose and MgSO4.7H2O 
concentrations on biomass production is showed in 
Figure 2. 
 
Table 2. Results of software analysis for optimization of 
biomass production in a milibioreactor 
The p-values provide evaluation of the    
significance of each variable. The p-values <0.05 
were considered as assurance of effective coefficient. 
p-values less than 0.05 represent the significance of 
the model terms [24]. The results of analysis are 



















































































0.5 2.5 4.5 6.5 
Predicted Cell mass (g l-1) 
Figure 1 Experimental data and the predicted values by 
the proposed model for cell mass production 
As shown, by increasing the maltose and 
MgSO4.7H2O concentrations towards +1 code, the rare 
of biomass production is increased. The optimum 





, respectively. M. purpureus produced 
the maximum biomass under the optimum condition 
including maltose 10 gl
-1





, MnSO4.H2O 0.5 gl
-1





, and pH=7 for 10 days. Under these conditions, 




3.3 Analysis of the data obtained from optimizing 
the lovastatin production 
The results of analysis are presented in Table 3. A 
and B represent maltose and magnesium sulfate 
concentrations, respectively . 
The experimental data using the software fitted 
into a multiple nonlinear regression model proposes 










According to Table 3, p-value is less than 0.05 for 
quadratic term of maltose concentration (A
2
) and the 
simultaneous impact of maltose and MgSO4.7H2O 
concentrations. In cases where the value of p is 
between 0.05 to 0.1. it is probably significant; so B 
term is provided in the model too. As a result, optimum 
monacolin K production is a function of the mentioned 
terms. R
2 
value of 0.80 was obtained for this equation. 
Figure 3 shows appropriate overlap of the experimental 
data and the predicted values by the proposed model 
for lovastatin production. The effectiveness of maltose 
and MgSO4.7H2O concentrations on lovastatin 
production is considered as well. By increasing of the 
MgSO4.7H2O concentration and decreasing the maltose 
concentration, lovastatin production is increased. All the 
response surfaces/contours could be analyzed for 
determining the optimized value of the factors, but it 
was difficult to analyze all of these simultaneously. 
Hence, point prediction of the design expert software 
was used to determine the optimum values of the 
factors for maximum lovastatin production. The 
maximum production of lovastatin under the optimum 
conditions was predicted as 0.208 abs. In order to 
proving the authenticity of optimal conditions, it was 
repeated in the mili-bioreactor again. Amount of 
lovastatin absorbance in 238 nm, 0.221 absorbance and 





BB Few studies are available about increasing of lovastatin 
production efficiency by M. purpureus in the liquid 
fermentation. Since optimization of numerous 
variables is time consuming and costly, other part of 
mentioned articles is focused to the use of statistical 
designs and data analysis software and predict of 
finally production in different concentration of 
effective factors. Good correlation between the 
predicting and experimental models confirms the value 
and importance of statistical methods for decreasing 
AA 
the number of experiments. 
Figure 2. Response surface and contour plots of maltose 
(A) and MgSO4.7H2O (B) on biomass production by M. 
purpureus 
 
Table 3. Results of software analysis for optimization of 































0.07 0.12 0.17 0.22 0.27 
predicted value 
 
Figure 3. Experimental data and the predicted values 
by the proposed model for lovastatin production 
Mansoori et al. 





In the present study, optimization of lovastatin 
production was carried out by M. purpureus in the 
mili-bioreactor. Maximum lovastatin yield can be 
achieved by reduction of maltose and increasing 
MgSO4.7H2O whereas mycelia production is not 
maximum. The mycelium production increase leads to 
rise of the medium viscosity, reduces ORT, and finally, 
reduces the desired metabolite production. In this 
study, we achieved the maximum production of 
lovastatin under optimal conditions including maltose 
10 gl
-1
, peptone 5 gl
-1





, KH2PO4 4 gl
-1
, thiamine 0.1 gl
-1
, 
and pH=7, air flow rate 1.8 Lmin
-1 
after 10 days. 
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